GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » ROIC %

NNVC (Nanoviricides) ROIC % : -162.23% (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Nanoviricides's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -162.23%.

As of today (2024-12-11), Nanoviricides's WACC % is 13.49%. Nanoviricides's ROIC % is -120.64% (calculated using TTM income statement data). Nanoviricides earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Nanoviricides ROIC % Historical Data

The historical data trend for Nanoviricides's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides ROIC % Chart

Nanoviricides Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -68.14 -84.53 -86.46 -101.01 -104.04

Nanoviricides Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -96.79 -106.53 -94.93 -120.70 -162.23

Competitive Comparison of Nanoviricides's ROIC %

For the Biotechnology subindustry, Nanoviricides's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's ROIC % distribution charts can be found below:

* The bar in red indicates where Nanoviricides's ROIC % falls into.



Nanoviricides ROIC % Calculation

Nanoviricides's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2024 is calculated as:

ROIC % (A: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2023 ) + Invested Capital (A: Jun. 2024 ))/ count )
=-8.516 * ( 1 - 0% )/( (8.494 + 7.876)/ 2 )
=-8.516/8.185
=-104.04 %

where

Nanoviricides's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-12.672 * ( 1 - 0% )/( (7.876 + 7.746)/ 2 )
=-12.672/7.811
=-162.23 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanoviricides  (AMEX:NNVC) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nanoviricides's WACC % is 13.49%. Nanoviricides's ROIC % is -120.64% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Nanoviricides ROIC % Related Terms

Thank you for viewing the detailed overview of Nanoviricides's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516